Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States

@article{Hoskin2012OpioidAD,
  title={Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States},
  author={P. J. Hoskin and G. W. Hanks},
  journal={Drugs},
  year={2012},
  volume={41},
  pages={326-344}
}
SummaryThe agonist-antagonist opioid analgesics are a heterogeneous group of drugs with moderate to strong analgesic activity comparable to that of the pure agonist opioids such as codeine and morphine but with a limited effective dose range. The group includes drugs which act as an agonist or partial agonist at one receptor and an antagonist at another (pentazocine, butorphanol, nalbuphine, dezocine) and drugs acting as a partial agonist at a single receptor (buprenorphine). These drugs can be… 
Pentazocine-Induced Antinociception Is Mediated Mainly by μ-Opioid Receptors and Compromised by κ-Opioid Receptors in Mice
TLDR
The results suggest pentazocine produces antinociception primarily via activation of μ-opioid receptors, but at high doses, this μ-OPioid receptor-mediated antinOCiception is antagonized by concomitant activation of κ-opIOid receptors.
Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.
TLDR
This hypothesis is that addiction caused by MOR-targeting analgesics could be blocked by blending in a new "antiaddiction" ingredient that does not diminish analgesia and does not introduce its own therapeutically limiting side effects, then continued clinical use of prescription opioids for treating pain could be maintained (or even enhanced) instead of curtailed.
Transnasal Butorphanol
TLDR
Transnasal butorphanol is a novel formulation of an established analgesic which appears suitable for the short term treatment of moderate to severe pain, especially in an ambulatory setting and may increase cardiac workload, as demonstrated by elevated values for cardiac index, stroke volume and left ventricular end diastolic pressure.
Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats
RationaleLow-efficacy mu opioid receptor agonists may be useful for some clinical indications, but clinically available low-efficacy mu agonists also have low selectivity for mu vs. kappa opioid
Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist
TLDR
It is identified that the analgesic effect of Dezocine was a result of action at both the κ and μ opioid receptors, and was a κ partial agonist and μpartial agonist.
Opioid receptor targeting ligands for pain management: a review and update
TLDR
Modifications of peptide structures have improved opioid receptor affinity, efficacy, stability, half-life and CNS penetrations, and modified opioid peptides and MDL ligands are potentially better analgesics than morphine.
"I'll Be Back": The Resurrection of Dezocine.
TLDR
The history and properties of dezocine are summarized and evidence and rationale for why deZocine has undergone a resurrection are presented, which could endow the drug with antinociceptive activity in neuropathic pain conditions.
Nalbuphine for postoperative pain treatment in children.
TLDR
Nalbuphine may be an useful opioid for postoperative use in children, but exact efficacy has not been determined yet and the exact risk for opioid-induced side effects and severe adverse events is still unclear.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 131 REFERENCES
Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs
TLDR
Pentazocine, buprenorphine, nalbuphine and butorphanol all demonstrate definite analgesic properties, and naltrexone, in contrast, has only limited agonist action, and is perhaps better regarded as an antagonist.
Analgesic effectiveness of the narcotic agonist-antagonists.
  • R. Houde
  • Biology, Medicine
    British journal of clinical pharmacology
  • 1979
TLDR
The major advantages of the partial agonists of the morphine-type over the nalorphine-type drugs are that they have not been found to produce psychotomimetic reactions, and they seem to have fewer potentially deleterious effects in cardiac patients.
The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.
TLDR
It has been shown that buprenorphine is a partial agonist of the mu type which both suppressed and precipitated abstinence in the morphine-dependent dog while morphine and propoxyphene are stronger agonists.
Buprenorphine: A Review of its Pharmacological Properties and Therapeutic Efficacy
TLDR
Buprenorphine appears to produce side effects which are similar to those seen with other morphine- like compounds, including respiratory depression, and animal studies and a direct addiction study in a few volunteers suggest that the dependence liability of buprenorphines may be lower than that of other older morphine-like drugs.
The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man.
TLDR
The data suggest a significant species difference in nalorphine effect in animals, and the difficulties involved in the formulation of clinically useful naloralorphine-morphine mixtures are discussed.
Crossover Trials in Clinical Analgesic Assays: Studies of Buprenorphine and Morphine
TLDR
Sublingual buprenorphine was found to be about 15 times as potent as intramuscular morphine and was well accepted by patients, and the main difference in results compared with the crossover studies was a decrease in efficiency and sensitivity.
Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
TLDR
Preliminary pharmacodynamic data indicate that the ceiling of analgesic activity of dezocine occurs at a higher level of analgesia than that of reference agonist/antagonist agents, and the drug exhibited a morphine-like degree of anaesthetic-sparing activity in animals.
Butorphanol and Morphine: A Double‐Blind Comparison of Their Parenteral Analgesic Activity
TLDR
The analgesic effects of butorphanol tartrate and morphine sulfate were compared in 127 patients judged to have moderate to severe pain following major operations to suggest thatbutorphanol is a safe, potent, and effective analgesic agent, with probably a low potential for inducing drug dependence.
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
TLDR
Nalbuphine appears to offer a useful alternative to morphine in patients with moderate to severe pain, and it appears to produce satisfactory anaesthesia when used as a component of a 'balanced' anaesthesia technique, although a relatively low 'ceiling' effect for reduction of anaesthetic requirements with nal Buphine may limit its usefulness in this regard.
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
TLDR
Nalbuphine appears to offer a useful alternative to morphine in patients with moderate to severe pain and appears to produce satisfactory anaesthesia when used as a component of a 'balanced' anaesthesia technique, although a relatively low 'ceiling' effect for reduction of anaesthetic requirements with nal Buphine may limit its usefulness.
...
1
2
3
4
5
...